Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Bristol-Myers Squibb Company (NYSE: BMY) securities.
If you suffered a loss on your Bristol-Myers Squibb Company investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Mar 19 2019 - Mar 19 2024
CASE DETAILS: The U.S. Food and Drug Administration (“FDA”) posted briefing documents in advance of meeting of the Oncologic Drugs Advisory Committee, scheduled for March 15, 2024, regarding Bristol Myers’s CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted by Bristol Myers. Following this news, on March 13, 2024, Bristol Myers’s stock price fell over 3%.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





